142 related articles for article (PubMed ID: 24470591)
21. Inhibition of neointima formation by local delivery of estrogen receptor alpha and beta specific agonists.
Krom YD; Pires NM; Jukema JW; de Vries MR; Frants RR; Havekes LM; van Dijk KW; Quax PH
Cardiovasc Res; 2007 Jan; 73(1):217-26. PubMed ID: 17141206
[TBL] [Abstract][Full Text] [Related]
22. Lymphoma Angiogenesis Is Orchestrated by Noncanonical Signaling Pathways.
Gloger M; Menzel L; Grau M; Vion AC; Anagnostopoulos I; Zapukhlyak M; Gerlach K; Kammertöns T; Hehlgans T; Zschummel M; Lenz G; Gerhardt H; Höpken UE; Rehm A
Cancer Res; 2020 Mar; 80(6):1316-1329. PubMed ID: 31932457
[TBL] [Abstract][Full Text] [Related]
23. Chemopreventive effect of ERβ-Selective agonist on intestinal tumorigenesis in Apc(Min/+) mice.
Giroux V; Bernatchez G; Carrier JC
Mol Carcinog; 2011 May; 50(5):359-69. PubMed ID: 21480389
[TBL] [Abstract][Full Text] [Related]
24. Intracellular lactate-mediated induction of estrogen receptor beta (ERβ) in biphasic malignant pleural mesothelioma cells.
Manente AG; Pinton G; Zonca S; Cilli M; Rinaldi M; Daga A; Nilsson S; Moro L
Oncotarget; 2015 Sep; 6(28):25121-34. PubMed ID: 26208479
[TBL] [Abstract][Full Text] [Related]
25. Anxiolytic effects and neuroanatomical targets of estrogen receptor-β (ERβ) activation by a selective ERβ agonist in female mice.
Oyola MG; Portillo W; Reyna A; Foradori CD; Kudwa A; Hinds L; Handa RJ; Mani SK
Endocrinology; 2012 Feb; 153(2):837-46. PubMed ID: 22186418
[TBL] [Abstract][Full Text] [Related]
26. Expression of Estrogen Receptor Beta Predicts Oncologic Outcome of pT3 Upper Urinary Tract Urothelial Carcinoma Better Than Aggressive Pathological Features.
Luo HL; Sung MT; Tsai EM; Lin CS; Lee NL; Chung YH; Chiang PH
Sci Rep; 2016 Apr; 6():24263. PubMed ID: 27052470
[TBL] [Abstract][Full Text] [Related]
27. β-LGND2, an ERβ selective agonist, inhibits pathologic retinal neovascularization.
Giddabasappa A; Eswaraka JR; Barrett CM; Bauler MN; Wu Z; Yepuru M; Miller DD; Dalton JT
Invest Ophthalmol Vis Sci; 2012 Jul; 53(8):5066-75. PubMed ID: 22714897
[TBL] [Abstract][Full Text] [Related]
28. Estrogen receptor beta growth-inhibitory effects are repressed through activation of MAPK and PI3K signalling in mammary epithelial and breast cancer cells.
Cotrim CZ; Fabris V; Doria ML; Lindberg K; Gustafsson JÅ; Amado F; Lanari C; Helguero LA
Oncogene; 2013 May; 32(19):2390-402. PubMed ID: 22751110
[TBL] [Abstract][Full Text] [Related]
29. Amelioration of Dalton's lymphoma-induced angiogenesis by melatonin.
Kumari R; Rawat K; Kumari A; Shrivastava A
Tumour Biol; 2017 Jun; 39(6):1010428317705758. PubMed ID: 28618962
[TBL] [Abstract][Full Text] [Related]
30. The inhibitory effect of diarylpropionitrile, a selective agonist of estrogen receptor beta, on the growth of MC38 colon cancer line.
Motylewska E; Stasikowska O; Mełeń-Mucha G
Cancer Lett; 2009 Apr; 276(1):68-73. PubMed ID: 19101081
[TBL] [Abstract][Full Text] [Related]
31. Estrogen receptor α and β in the normal immune system and in lymphoid malignancies.
Yakimchuk K; Jondal M; Okret S
Mol Cell Endocrinol; 2013 Aug; 375(1-2):121-9. PubMed ID: 23707618
[TBL] [Abstract][Full Text] [Related]
32. Endogenous estrogen receptor beta is transcriptionally active in primary ovarian cells from estrogen receptor knockout mice.
Mueller SO; Katzenellenbogen JA; Korach KS
Steroids; 2004 Sep; 69(10):681-6. PubMed ID: 15465114
[TBL] [Abstract][Full Text] [Related]
33. Tumour-suppressive effect of oestrogen receptor β in colorectal cancer patients, colon cancer cells, and a zebrafish model.
Topi G; Satapathy SR; Dash P; Fred Mehrabi S; Ehrnström R; Olsson R; Lydrup ML; Sjölander A
J Pathol; 2020 Jul; 251(3):297-309. PubMed ID: 32333795
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of vascular endothelial growth factor reduces angiogenesis and modulates immune cell infiltration of orthotopic breast cancer xenografts.
Roland CL; Dineen SP; Lynn KD; Sullivan LA; Dellinger MT; Sadegh L; Sullivan JP; Shames DS; Brekken RA
Mol Cancer Ther; 2009 Jul; 8(7):1761-71. PubMed ID: 19567820
[TBL] [Abstract][Full Text] [Related]
35. Estrogen receptor-β signaling modulates epithelial barrier function.
Looijer-van Langen M; Hotte N; Dieleman LA; Albert E; Mulder C; Madsen KL
Am J Physiol Gastrointest Liver Physiol; 2011 Apr; 300(4):G621-6. PubMed ID: 21252046
[TBL] [Abstract][Full Text] [Related]
36. Estrogen Receptor β in the Nucleus Accumbens Regulates the Rewarding Properties of Cocaine in Female Mice.
Satta R; Certa B; He D; Lasek AW
Int J Neuropsychopharmacol; 2018 Apr; 21(4):382-392. PubMed ID: 29294029
[TBL] [Abstract][Full Text] [Related]
37. Estrogen Receptor-β Up-Regulates IGF1R Expression and Activity to Inhibit Apoptosis and Increase Growth of Medulloblastoma.
Cookman CJ; Belcher SM
Endocrinology; 2015 Jul; 156(7):2395-408. PubMed ID: 25885794
[TBL] [Abstract][Full Text] [Related]
38. Contribution of estrogen receptor subtypes, ERα, ERβ, and GPER1 in rapid estradiol-mediated enhancement of hippocampal synaptic transmission in mice.
Kumar A; Bean LA; Rani A; Jackson T; Foster TC
Hippocampus; 2015 Dec; 25(12):1556-66. PubMed ID: 25980457
[TBL] [Abstract][Full Text] [Related]
39. Antitumor effects of bevacizumab in a microenvironment-dependent human adult T-cell leukemia/lymphoma mouse model.
Mori F; Ishida T; Ito A; Sato F; Masaki A; Narita T; Suzuki S; Yamada T; Takino H; Ri M; Kusumoto S; Komatsu H; Hishizawa M; Imada K; Takaori-Kondo A; Niimi A; Ueda R; Inagaki H; Iida S
Eur J Haematol; 2014 Mar; 92(3):219-28. PubMed ID: 24188416
[TBL] [Abstract][Full Text] [Related]
40. Selective Estrogen Receptor β Agonist LY500307 as a Novel Therapeutic Agent for Glioblastoma.
Sareddy GR; Li X; Liu J; Viswanadhapalli S; Garcia L; Gruslova A; Cavazos D; Garcia M; Strom AM; Gustafsson JA; Tekmal RR; Brenner A; Vadlamudi RK
Sci Rep; 2016 Apr; 6():24185. PubMed ID: 27126081
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
